3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
26
Triple Negative Breast Neoplasms
13
Prostatic Neoplasms
12
Ovarian Neoplasms
12
Neoplasms
10
Neoplasm Metastasis
8
Fallopian Tube Neoplasms
6
Leukemia, Myeloid, Acute
5
Small Cell Lung Carcinoma
4
Pancreatic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Recurrence
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
mCRPC
1
Wilms Tumor
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Thrombocythemia, Essential
1
Solid Tumor
1
Sarcoma
1
Interventions
padeliporfin
5
darolutamide
3
Pluvicto
3
enzalutamide
2
apalutamide
2
Radiotherapy
2
Nivolumab
2
Androgen Antagonists
2
Abiraterone Acetate
2
talazoparib
1
sipuleucel-T
1
palladium-bacteriopheophorbide
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
ixabepilone
1
gedatolisib
1
gallium 68 PSMA-11
1
abiraterone
1
Therapeutics
1
Tamsulosin
1
Standard of Care
1
Robotic Surgical Procedures
1
Prostate-Specific Antigen
1
Prednisone
1
Paclitaxel
1
Oxygen
1
Nitrous Oxide
1
Microtubule-Associated Proteins
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Diseases
×
talazoparib
×
Clear all
NCT06582628
2024-12-02
TEAM PC
Fundacion Oncosur
Phase 2
Recruiting
78 enrolled